Free access to Euretos AI Platform for academic researchers

The Euretos AI Platform — claimed to offer access to the world’s most extensive machine-read knowledge base focused on molecular disease and drug research — is now free to access for all academic users, meaning the integrated data, toolset and workflows that have long been used by the corporate research community in drug development are now being made available to the academic research community.

The platform provides intelligent and proactive search capabilities, powerful and intuitive analytics functions, visualised relation maps and many specific workflows for data-driven disease insights such as for target assessment. In addition, it contains curated public data, such as a comprehensive cell type expression library.

Biological research technologies have advanced significantly over the last two decades, leading to an explosion in the publication of scientific papers and research data covering increasing molecular diversity and more significant manipulation and understanding of biological systems. Until now, few tools were available to navigate this wealth of information and to assess the relevance for each biologist’s research projects.

The Euretos AI Platform provides an integrated view of publications and relevant research data in combination with user-friendly features and workflows to enhance fundamental disease and drug research productivity. For example, users can create gene sets from literature automatically and overlay them with the results of their wet-lab experiments and understand how these are enriched in the various relevant cell types. From there, biologists can infer the molecular pathways explaining their experimental results, all without depending on bioinformatics experts.

“The Euretos AI Platform is currently being used with some of the largest pharma and biotech companies in the world as well as in a number of large public–private partnerships,” said Euretos CEO Aram Krol. “By making our platform available for free for academic researchers, who are mainly involved in fundamental early disease research, we want to make our contribution to supporting this crucial early investigative effort.”

To access the platform now, click here.

Image credit: ©stock.adobe.com/au/WavebreakMediaMicro

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.